Outcome of early-treated type III Gaucher disease patients

Blood Cells, Molecules, and Diseases

Volumn 53, Issue 3, 2014, Pages 105-109

  Lee, Ni Chung ^a   Chien, Yin Hsiu ^a   Wong, Siew Lee ^b   Sheen, Jiunn Ming ^c   Tsai, Fuu Jen ^d   Peng, Shinn Forng ^a   Leung, Joseph Hang ^b   Chao, Mei Chyn ^e   Shun, Chia Tung ^a   Hwu, Wuh Liang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Enzyme replacement therapy; Lymphadenopathy; Mental retardation; Neuropathic; P.L444P mutation; Type IIIB Gaucher disease

Indexed keywords

CHITOTRIOSIDASE; HEMOGLOBIN; IMIGLUCERASE; GLUCOSYLCERAMIDASE; RECOMBINANT PROTEIN;

ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; FEMALE; GAUCHER DISEASE; GAZE PARALYSIS; HEPATOSPLENOMEGALY; HUMAN; KYPHOSIS; LYMPHADENOPATHY; MALE; MENTAL DEFICIENCY; OSTEOPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; SEIZURE; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENZYME REPLACEMENT; FOLLOW UP; GENETICS; INFANT; LYMPH NODE; LYMPHATIC DISEASES; PATHOLOGY;

BIOPSY; CHILD, PRESCHOOL; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; INFANT; LYMPH NODES; LYMPHATIC DISEASES; MALE; RECOMBINANT PROTEINS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84904733709     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.05.007     Document Type: Article

References (33)

1. Brady R.O., Kanfer J.N., Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun. 1965, 18:221-5.
2. Beutler E., Grabowski G. Gaucher disease. The Metabolic and Molecular Bases of Inherited Diseases 1995, 2641-2670. McGraw-Hill, New York. C. Scriver, A. Beaudet, W. Sly, D. Valle (Eds.).
3. Weinreb N.J., Charrow J., Andersson H.C., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry. Am. J. Med. 2002, 113:112-119.
4. Bove K.E., Daugherty C., Grabowski G.A. Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Hum. Pathol. 1995, 26:1040-1045.
5. Dreborg S., Erikson A., Hagberg B. Gaucher disease-Norrbottnian type. I. General clinical description. Eur. J. Pediatr. 1980, 133:107-118.
6. Erikson A., Astrom M., Mansson J.E. Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease. Neuropediatrics 1995, 26:203-207.
7. Dahl N., Lagerstrom M., Erikson A., Pettersson U. Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am. J. Hum. Genet. 1990, 47:275-8.
8. Park J.K., Orvisky E., Tayebi N., et al. Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr. Res. 2003, 53:387-395.
9. Wan L., Hsu C.M., Tsai C.H., et al. Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. Blood Cells Mol. Dis. 2006, 36:422-425.
10. Ida H., Rennert O.M., Iwasawa K., Kobayashi M., Eto Y. Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Hum. Genet. 1999, 105:120-126.
11. Tajima A., Yokoi T., Ariga M., et al. Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol. Genet. Metab. 2009, 97:272-277.
12. Patterson M.C., Horowitz M., Abel R.B., et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. Neurology 1993, 43:1993-1997.
13. Abrahamov A., Elstein D., Gross-Tsur V., et al. Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet 1995, 346:1000-1003.
14. Davies E.H., Erikson A., Collin-Histed T., et al. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J. Inherit. Metab. Dis. 2007, 30:935-942.
15. Chien Y.H., Lee N.C., Tsai F.J., Chao M.C., Hwu W.L. Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease. Mol. Genet. Metab. 2010, 101:90-91.
16. Altarescu G., Hill S., Wiggs E., et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr. 2001, 138:539-547.
17. Kraoua I., Sedel F., Caillaud C., et al. A French experience of type 3 Gaucher disease: phenotypic diversity and neurological outcome of 10 patients. Brain Dev. 2011, 33:131-139.
18. Lee B.H., Kim D.Y., Kim G.H., et al. Progressive mesenteric lymphadenopathy with protein-losing enteropathy; a devastating complication in Gaucher disease. Mol. Genet. Metab. 2012, 105:522-524.
19. Tantawy A.A., Sherif E.M., Adly A.A., Hassanine S., Awad A.H. Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience. J. Inherit. Metab. Dis. 2013, 36:1025-1037.
20. Santamaria F., Parenti G., Guidi G., et al. Pulmonary manifestations of Gaucher disease: an increased risk for L444P homozygotes?. Am. J. Respir. Crit. Care Med. 1998, 157:985-989.
21. Lo S.M., Liu J., Chen F., et al. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J. Inherit. Metab. Dis. 2011, 34:643-650.
22. Suwannarat P., Keeratichamroen S., Wattanasirichaigoon D., et al. Molecular characterization of type 3 (neuronopathic) Gaucher disease in Thai patients. Blood Cells Mol. Dis. 2007, 39:348-352.
23. Vellodi A., Tylki-Szymanska A., Davies E.H., et al. Management of neuronopathic Gaucher disease: revised recommendations. J. Inherit. Metab. Dis. 2009, 32:660-664.
24. Cox-Brinkman J., van Breemen M.J., van Maldegem B.T., et al. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J. Inherit. Metab. Dis. 2008, 31:745-752.
25. Zimran A., Altarescu G., Elstein D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis. 2013, 50:134-137.
26. Lim A.K., Vellodi A., McHugh K. Mesenteric mass in a young girl-an unusual site for Gaucher's disease. Pediatr. Radiol. 2002, 32:674-676.
27. Burrow T.A., Cohen M.B., Bokulic R., et al. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy. J. Pediatr. 2007, 150:202-206.
28. Burrow T., Witte D., Bailey L., et al. Abnormal pathology findings in a patient with Gaucher disease type 3 treated with enzyme replacement therapy. Mol. Genet. Metab. 2013, 108:S27-S27.
29. Yagci B., Salor O., Yalcin B., et al. Giant lymphadenopathy infiltrated by Gaucher cells mimicking lymphoma. Pediatr. Blood Cancer 2009, 52:870-871.
30. Fowler D.J., Weber M.A., Anderson G., et al. Ultrastructural features of Gaucher disease treated with enzyme replacement therapy presenting as mesenteric mass lesions. Fetal Pediatr. Pathol. 2006, 25:241-248.
31. Levy J.M., Glass D.A., Rodriguez K.H. An unusual presentation of Gaucher disease in an infant with progressive dyspnea. Ochsner J. 2013, 13:270-272.
32. Perez-Colon E., Sanchez-Valle A., Patel S., Murphy M. Mesenteric Gaucher cell pseudotumor - a rare cause for diarrhea and tetany in a 19year-old Gaucher's Type 3b patient. Journal of Inherited Metabolic Disease 2013, S274. (Barcelona, Spain). J. Zschocke, K.M. Gibson (Eds.).
33. Abdelwahab M. Mesenteric and mediastinal lymphadenopathy in Egyptian children with Gaucher disease: a study of 6 patients: can enzyme replacement therapy (ERT) play a role in improving their condition?. 10th European Working Group on Gaucher Disease 2012, 37. (Paris, France). S. Dahl, M. Horowitz, H. Michelakakis, N. Belmatoug (Eds.).